Volume 27, Number 1—January 2021
Research Letter
Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA
Table
Race or ethnicity | Positive no./total no. (% of sample) | Residents >18 y, no. (% of population)* | Any infection, raw,† % (95% CI) | Any infection, weighted,‡ % (95% CI) | Weighted point prevalence,§ % (95% CI) | Weighted seroprevalence,¶ % (95% CI) |
---|---|---|---|---|---|---|
Total | 128/2138 (100) | 551,185 (100) | 6.0 (5.0–7.1) | 6.6 (5.7–7.7) | 3.0 (2.3–3.7) | 3.6 (2.8–4.4) |
White alone | 54/1431 (66.9) | 332,445 (60.3) | 3.8 (2.9–4.9) | 4.2 (3.2–5.2) | 2.4 (1.6–3.2) | 1.8 (1.1–2.5) |
Black or African American alone | 57/516 (24.1) | 177,950 (32.3) | 11.0 (8.5–14.1) | 11.0 (8.5–14.1) | 3.5 (1.9–5.1) | 7.5 (5.2–9.8) |
Asian alone | 2/59 (3.4) | 13,630 (2.5) | 3.4 (0.4–11.7) | 3.5 (0.0–8.2) | 1.7 (0.0–9.1) | 1.7 (0.0–9.1) |
Other# | 1/28 (1.3) | 7,025 (1.3) | 3.6 (0.1–18.4) | 2.7 (0.0–8.7) | 0.0 | 2.7 (0.0–8.7) |
Hispanic or Latino, any race | 14/104 (4.9) | 20,125 (3.7) | 13.5 (7.6–21.6) | 11.8 (5.6–18.0) | 10.1 (4.3–15.9) | 1.6 (0.0–4.0) |
*Census 2018 population estimates. By August 2, 2020, a total of 17,093 state-aggregated, confirmed cases had been reported in Ascension, East Baton Rouge, Livingston, and West Baton Rouge parishes (4). †Percentage of sample with a PCR-positive test, an IgG-positive test, or both. ‡Census-weighted percentage of PCR-positive test, IgG-positive test, or both calculated to match 2018 racial demographics by parish and combined. §Census-weighted percentage of PCR-positive and IgG-negative tests calculated to match 2018 racial demographics by parish and combined. ¶Census-weighted percentage of IgG–positive tests calculated to match 2018 racial demographics by parish and combined. #Other includes American Indian or Alaska Native, Pacific Islander, and multiracial persons.
References
- Feehan AK, Fort D, Garcia-Diaz J, Price-Haywood EG, Velasco C, Sapp E, et al. Seroprevalence of SARS-CoV-2 and infection fatality ratio, Orleans and Jefferson parishes, Louisiana, USA, May 2020. Emerg Infect Dis. 2020;26:2766–9. DOIPubMedGoogle Scholar
- Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al.; ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396:535–44. DOIPubMedGoogle Scholar
- Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 sites in the United States, March 23–May 12, 2020. JAMA Intern Med. 2020 Jul 21 [Epub ahead of print].
- Louisiana Department of Public Health. Louisiana coronavirus COVID-19 information [cited 2020 Sep 20]. http://ldh.la.gov/Coronavirus
- Feehan A, Fort D, Garcia-Diaz J, Price-Haywood E, Velasco C, Sapp E, et al. Frequency of symptoms and asymptomatic SARS-CoV-2 infection in New Orleans, Louisiana after 7 weeks of a stay-at-home order [cited 2020 Sep 8]. https://ssrn.com/abstract=3633166
- US Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody testing [cited 2020 Aug 10]. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html
- Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. J Clin Microbiol. 2020;58:e00941–20. DOIPubMedGoogle Scholar